Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Sudo Biosciences
Biopharma Co. Taps Veteran Biotech GC As First CLO
Sudo Biosciences, a company that develops medicines for neurological and immunological conditions such as multiple sclerosis, has named an experienced biotechnology industry general counsel as its first-ever chief legal officer.... Want to continue reading?
Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel
Sudo Biosciences, (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Paul S. Bavier, J.D., as Chief Legal Officer. Mr. Bavier brings more than two decades of legal and executive leadership experience in the biotechnology industry, with deep expertise spanning company formation, financings, mergers and acquisitions, compliance, and public market readiness.
Sudo Biosciences Announces Positive Phase 1 Results for Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550
- SUDO-550 demonstrated favorable safety, tolerability, and once-daily pharmacokinetic profile with full central nervous system (CNS) penetration - Achieved exposure levels associated with >90% inhibition of TYK2-mediated signaling in both the CNS and peripheral circulation - Phase 2 study in multiple sclerosis (MS) expected to begin in the first half of 2026 Sudo Biosciences, (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine...
Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550
- SUDO-550 is a potential best-in-class, orally administered, brain-penetrant TYK2 inhibitor being developed for the treatment of neuroinflammatory diseases. - Phase 1 clinical trial supported by preclinical data demonstrating high potency, selectivity, and efficacy in preclinical models, along with the ability to cross the blood-brain barrier.
Sudo Biosciences: Second Close Of Upsized Series B Funding Round Completed, Bringing Total To $147 Million
Sudo Biosciences – a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors – announced that during January 2024, it completed a second close of its Series B financing, raising an additional $30 million from new investors Dementia Discovery Fund (DDF, a SV Health Investors Fund), Leaps by Bayer, and UPMC Enterprises (the innovation, commercialization and venture capital arm of UPMC).
Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
The funding will advance two precision TYK2 inhibitors into the clinic for multiple sclerosis, psoriasis and other severe autoimmune and neurologic conditions. New investors include Dementia Discovery Fund, Leaps by Bayer, and UPMC Enterprises.
Form D Sudo Biosciences, Inc.
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Sudo Biosciences: $116 Million Raised To Develop Precision TYK2 Inhibitors
Sudo Biosciences – a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors – recently announced the close of a $116 million Series B financing round co-led by Enavate Sciences and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Surveyor Capital , Monograph Capital, and Eventide Asset Management and existing investors Frazier Life...
Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in-Class TYK2 Therapeutics Programs into the Clinic
Funding to advance potential first- and best-in-class brain-penetrant TYK2 candidate in multiple sclerosis and potential first- and best-in-class topical dermal TYK2 candidate in psoriasis into the clinic. Top-tier life science investor syndicate co-led by Enavate Sciences and TPG, with participation from Sanofi Ventures, Surveyor Capital (a Citadel company), Monograph Capital, Eventide Asset Management and existing investors Frazier Life Sciences and Velosity Capital.
Sudo Biosciences appoints new Chief Business Officer
Sudo Biosciences, a biopharmaceutical company that designs and develops a broad pipeline of TYK2 (tyrosine kinase 2) inhibitors, has announced the appointment of Imran Babar, Ph.D., as chief business officer. Dr Babar has extensive experience in in healthcare strategy, life sciences finance, operations and business development.
Stock Market | bentoncourier.com | 501-315-8228
Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Imran Babar, Ph.D., as chief business officer. Dr. Babar is an accomplished industry leader with broad experience in healthcare strategy, life sciences finance, operations and business development.
Stock Market | bentoncourier.com | 501-315-8228
Funding is being used to discover and develop a broad pipeline of precision TYK2 therapeutics Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the close of $37M in Series A financing led by Frazier Life Sciences (“Frazier”) and Velosity Capital. The Series A funding will be used primarily to advance Sudo’s lead drug candidates into the clinic.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Sudo
Contact Sudo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack